Navigation Links
LSTM to lead $30 million research program into malaria in pregnancy

The Liverpool School of Tropical Medicine has received a $30 million grant from the Bill & Melinda Gates Foundation to improve the control and treatment of malaria in pregnancy in Africa, Asia and Latin America. The five year programme will directly benefit the 50 million women who face exposure to malaria whilst pregnant every year.

The grant will fund research at Liverpool and at 38 partner institutions in 27 countries around the world. The research consortium is also supported by the European Union, and is seeking additional funding from other donors.

Malaria in pregnancy is a major cause of severe maternal anaemia and preventable low birth weight in infants, which greatly increases risk of death. It is estimated that more effective control of malaria in pregnancy could save the lives of up to 100,000 children every year in Africa alone.

There is less detailed information on the effects of malaria in pregnancy outside Africa. Although transmission rates are lower, natural immunity is also lower, therefore the consequences of malaria infection are more often severe, with a much higher risk of the death of the mother, baby or both.

The primary aims of the research address four key areas:


  • Obtain a better understanding of the burden of malaria in pregnancy in regions outside Africa where malaria is common.


  • Further evaluate which of the new generation of antimalarial drugs can be used safely and effectively for the treatment of pregnant women with malaria in Africa, Asia and Latin America.


  • Identify safe alternative antimalarials for the prevention of malaria in pregnancy in Africa to replace the commonly used drug sulphadoxine-pyrimethamine (to which many malaria parasites have developed resistance).

  • Determine the most effective combinations of drugs and other tools that reduce the risk of mosquito bites (eg insecticide treated bednets), thus preventing malaria in pregnancy.

  • Evaluate new interventions for the control of malaria in pregnancy in low transmission regions outside of Africa.

Coverage and utilisation

  • Establish the best way to increase the coverage and utilisation of existing strategies to control malaria in pregnancy.

Consortium leader Dr Feiko ter Kuile explained: In contrast to the recent focus on preventing malaria deaths in young children, the impact of malaria in pregnancy has until now been a relatively neglected area of research. This grant provides researchers from all over the world with the opportunity to conduct a much expanded and much needed research programme that is focussed on this other high risk group.

There are four main research theme areas consisting of ten major projects. The work is conducted jointly by expert institutions from all over the world that have agreed to use standardized methods and share information. This consortium approach generates a new momentum of life-saving research, which will provide evidence-based policy changes in the shortest possible time.

Defeating malaria will require new and better tools to prevent and treat the disease in pregnancy, said Dr Regina Rabinovich, director of Infectious Diseases Development at the Gates Foundation. By undertaking this important research, Liverpool and its partners will help bring the world closer to the ultimate goal of malaria eradication.


Contact: Alan Hughes
Liverpool School of Tropical Medicine

Related medicine news :

1. Alleged Multi-Million Dollar Fraud Ring Target of Federal Lawsuit
2. Whole Planet Foundation(TM) (a Whole Foods Market Foundation) and Nobel Peace Prize Winner Dr. Muhammad Yunus Partner With Natural Foods Vendors, Pledging Over $1 Million to Help Combat Poverty
3. New Jersey Healthcare Consulting Firm to Pay U.S. $2.875 Million to Resolve Allegations of Medicare Fraud
4. Trevena, Inc. Announces $24 Million Series A Financing
5. Cathedral Healthcare System to Pay U.S. $5.3 Million to Resolve Allegations Involving Inflated Charges to Obtain Higher Medicare Reimbursement
6. LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
7. Robert H. Smith Feeding the Future with $15 Million Gift to Hebrew University of Jerusalem
8. Kidney Patient Advocacy Community Joins National Effort to Raise Awareness about Health Crisis Impacting more than 26 Million Americans
9. Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million
10. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
11. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: